Context Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
CNTX Nasdaq 8731 http://www.contexttherapeutics.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Context Therapeutics Inc

Context Therapeutics Reports Full Year 2022 Financial Results and Recent Pipeline Updates - Mar 22nd, 2023 9:08 pm
Context Therapeutics Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023 - Mar 15th, 2023 11:30 am
UPDATE -- Diamond Equity Research Initiates Coverage on Context Therapeutics Inc. (NASDAQ: CNTX) - Feb 13th, 2023 1:52 pm
Lab Notes: Center for Breakthrough Medicines expands offerings; Researchers identify key 'gene signature' - Feb 10th, 2023 6:36 pm
Context Therapeutics announces positive responses in Phase 2 OATH clinical trial - Feb 7th, 2023 5:21 pm
Context Therapeutics Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial Cancer - Feb 6th, 2023 12:30 pm
Context Therapeutics’ Clinical Partner Stemline Therapeutics, a Subsidiary of Menarini Group Receives FDA Approval of ORSERDU™ (elacestrant) in ER+, HER2-, ESR1-mutated Breast Cancer - Jan 31st, 2023 12:30 pm
Context Therapeutics and Lonza Enter Manufacturing Agreement for Bispecific Antibody Targeting Claudin 6-Positive Cancers - Jan 9th, 2023 12:30 pm
Context Therapeutics® Highlights 2023 Corporate Priorities and Pipeline Milestones - Jan 4th, 2023 12:30 pm
Context Therapeutics® Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast Cancer - Dec 8th, 2022 12:30 pm
Context Therapeutics® Nominates CTIM-76 Bispecific Antibody Candidate to Develop Treatment for Claudin 6-Positive Solid Tumors - Nov 29th, 2022 12:30 pm
Is Context Therapeutics (NASDAQ:CNTX) In A Good Position To Invest In Growth? - Nov 27th, 2022 12:36 pm
Context Therapeutics® Announces Clinical Updates on ONA-XR to be Presented at 2022 San Antonio Breast Cancer Symposium - Nov 21st, 2022 2:11 pm
Context Therapeutics® Reports Third Quarter 2022 Operating and Financial Results - Nov 9th, 2022 9:14 pm
Context Therapeutics to Participate in the ThinkEquity Conference - Oct 20th, 2022 11:30 am
Context Therapeutics® Amends Cash Guidance, Extends Runway into Q1 2024 - Sep 27th, 2022 11:30 am
A number of insiders bought Context Therapeutics Inc. (NASDAQ:CNTX) stock last year, which is great news for shareholders - Sep 6th, 2022 4:50 pm
Context Therapeutics® to Participate in the H.C. Wainwright 24th Annual Global Investment Conference - Sep 6th, 2022 11:30 am
Context Therapeutics® Reports Second Quarter 2022 Operating and Financial Results - Aug 11th, 2022 8:01 pm
Context Therapeutics and The Menarini Group Announce Clinical Trial Collaboration and Supply Agreement to Evaluate ONA-XR and Elacestrant Combination - Aug 2nd, 2022 2:49 pm